Ose Immunotherapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Ose Immunotherapeutics R&D Spending Growth & History (OSE)
Ose Immunotherapeutics's r&d spending was €33.9M for fiscal 2025.
View full Ose Immunotherapeutics company overviewOse Immunotherapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €33.9M | €3.5M | +11.46% |
| 2024 | 2024-12-31 | €30.4M | €13.3M | +77.44% |
| 2023 | 2023-12-31 | €17.2M | −€9.7M | −36.20% |
| 2022 | 2022-12-31 | €26.9M | −€3.7M | −11.97% |
| 2021 | 2021-12-31 | €30.6M | €8.2M | +36.66% |
| 2020 | 2020-12-31 | €22.4M | — | — |
Ose Immunotherapeutics r&d spending trends
Over the last five fiscal years, Ose Immunotherapeutics's r&d spending increased from €22.4M to €33.9M, a change of €11.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
reported R&D expense
TickerStat standardizes research and development expense reported in company official filings, including the software-specific standardized R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ose Immunotherapeutics source filings ↗